7-chloro-5-methyl-2-methylthio-3-phenylsulfonylpyrazolo[1,5-a]pyrimidine | 243660-91-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 7-chloro-5-methyl-2-methylthio-3-phenylsulfonylpyrazolo[1,5-a]pyrimidine
• 英文别名: 3-benzenesulphonyl-7-chloro-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidine；3-(benzenesulfonyl)-7-chloro-5-methyl-2-methylsulfanylpyrazolo[1,5-a]pyrimidine
• CAS: 243660-91-5
• 化学式: C₁₄H₁₂ClN₃O₂S₂
• 分子量: 353.853
• InChiKey: YPAKCUFDMDPCIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  98
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-chloro-5-methyl-2-methylthio-3-phenylsulfonylpyrazolo[1,5-a]pyrimidine 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 苯 为溶剂， 反应 2.0h， 以22%的产率得到5-methyl-2-methylthio-3-phenylsulfonyl-pyrazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  Synthesis and SAR of 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines as potent serotonin 5-HT6 receptor antagonists

  摘要：

  Syntheses of a series of novel 3-sulfonyl-pyrazolo[1,5-a]pyrimidines and their 5-HT6 receptor antagonistic structure-activity relationship are disclosed. The nature and position of substituents, which affect their receptor antagonistic activity, are analyzed. Among all synthesized derivatives, {3-(3-chlorophenylsulfonyl)-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-2-yl}-methyl-amine 33 (K-i = 190 pM), (3-phenylsulfonyl-7-methyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine 44 (K-i = 240 pM), (3-phenylsulfonyl-5-metoxymethyl-7-methyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine 50 (K-i = 270 pM), and (3-phenylsulfonyl-5-methyl-7-metoxymethyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine 52 (K-i = 280 pM) are the most potent antagonists of the 5-HT6 receptors. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.12.055
• 作为产物：
  描述：

  3-benzenesulphonyl-5-methyl-2-methylsulphanyl-pyrazolo[1,5-a]pyrimidin-7-ol 以 ice-water 、 三氯氧磷 为溶剂， 以3.0 g (94%)的产率得到7-chloro-5-methyl-2-methylthio-3-phenylsulfonylpyrazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  Pyrazolopyrimidine and pyrazolines and process for preparation thereof

  摘要：

  本发明涉及一般式的吡唑吡嘧啶和吡唑三嗪，以及它们的药用盐。令人惊讶的是，这些化合物表现出对5HT-6受体的选择性亲和力。因此，它们适用于治疗和预防中枢神经系统疾病，例如精神病、精神分裂症、躁郁症、抑郁症、神经系统疾病、记忆障碍、帕金森病、肌萎缩侧索硬化、阿尔茨海默病和亨廷顿舞蹈症。

  公开号：

  US06194410B1

文献信息

• SUBSTITUTED 3-ARYLSULFONYL-PYRAZOLO[1,5-A]PYRIMIDINES, SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS AND METHODS FOR THE PRODUCTION AND USE THEREOF
  申请人：Ivashchenko Andrey Alexandrovich

  公开号：US20110178078A1

  公开（公告）日：2011-07-21

  The invention relates to the novel substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines of the general formula 1, pharmaceutically acceptable salts and/or hydrates thereof, serotonin 5-HT 6 receptor antagonists and pharmaceutical compositions, and also to method for prophylaxis and treatment of various diseases of central nervous system at humans and warm-blooded animals pathogenesis of which is associated with serotonin 5-HT 6 receptors, in particular, Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, and other neurodegenerative diseases, cognitive disorders and obesity. In the general formula 1: wherein: X═S, SO or NH; R 1 represents hydrogen, optionally substituted C 1 -C 3 alkyl, cycloalkyl, adamantyl, aryl or heterocyclyl; R 2 represents hydrogen, halogen, optionally substituted C 1 -C 3 alkyl, substituted hydroxyl, aryldiazenyl or optionally substituted amino group; R 3 represents hydrogen, optionally substituted C 1 -C 3 alkyl, substituted hydroxyl, pyridyl or optionally substituted amino group, besides, in cases when X═S or X═NH, at least one of R 1 , R 2 or R 3 represent substituted C 1 -C 3 alkyl, cycloalkyl, adamantyl, aryl, heterocyclyl, halogen, substituted hydroxyl, optionally substituted amino group, aryldiazenyl, or at least two of R 1 , R 2 or R 3 represent hydrogen; R 4 represents C 1 -C 3 alkyl; R 5 represents hydrogen, one or two halogens, C 1 -C 3 alkyl or optionally substituted hydroxyl.

  该发明涉及新的取代的3-芳基磺酰基吡唑并[1,5-a]嘧啶，其通式为1，其药学上可接受的盐和/或水合物，血清素5-HT6受体拮抗剂和制药组合物，以及用于预防和治疗与血清素5-HT6受体相关的中枢神经系统各种疾病的方法，特别是阿尔茨海默病、帕金森病、亨廷顿病、精神分裂症和其他神经退行性疾病、认知障碍和肥胖症。在通式1中：其中：X═S、SO或NH；R1代表氢、可选取代的C1-C3烷基、环烷基、金刚烷基、芳基或杂环基；R2代表氢、卤素、可选取代的C1-C3烷基、取代的羟基、芳基重氮基或可选取代的氨基基团；R3代表氢、可选取代的C1-C3烷基、取代的羟基、吡啶基或可选取代的氨基基团，此外，在X═S或X═NH的情况下，至少有R1、R2或R3中的一个代表取代的C1-C3烷基、环烷基、金刚烷基、芳基、杂环基、卤素、取代的羟基、可选取代的氨基基团、芳基重氮基，或者R1、R2或R3中的至少两个代表氢；R4代表C1-C3烷基；R5代表氢、一个或两个卤素、C1-C3烷基或可选取代的羟基。
• Pyrazolopyrimidines and pyrazolotriazines with 5-HT6 receptor affinity
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0941994B1

  公开（公告）日：2003-05-14
• US6194410B1
  申请人：——

  公开号：US6194410B1

  公开（公告）日：2001-02-27
• Pyrazolopyrimidine and pyrazolines and process for preparation thereof
  申请人：Hoffman-La Roche Inc.

  公开号：US06194410B1

  公开（公告）日：2001-02-27

  The present invention is concerned with pyrazolopyrimidines and pyrazolotriazines of the general formula and their pharmaceutically acceptable salts. Surprisingly, these compounds evidence selective affinity to 5HT-6 receptors. They are accordingly suitable for use in the treatment and prevention of central nervous disorders such as, for example, psychoses, schizophrenia, manic depressions, depressions, neurological disorders, memory disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's chorea.

  本发明涉及一般式的吡唑吡嘧啶和吡唑三嗪，以及它们的药用盐。令人惊讶的是，这些化合物表现出对5HT-6受体的选择性亲和力。因此，它们适用于治疗和预防中枢神经系统疾病，例如精神病、精神分裂症、躁郁症、抑郁症、神经系统疾病、记忆障碍、帕金森病、肌萎缩侧索硬化、阿尔茨海默病和亨廷顿舞蹈症。
• Synthesis and SAR of 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines as potent serotonin 5-HT6 receptor antagonists
  作者：Alexandre V. Ivachtchenko、Elena S. Golovina、Madina G. Kadieva、Volodymyr M. Kysil、Oleg D. Mitkin、Sergey E. Tkachenko、Ilya Okun

  DOI：10.1016/j.bmc.2010.12.055

  日期：2011.2

  Syntheses of a series of novel 3-sulfonyl-pyrazolo[1,5-a]pyrimidines and their 5-HT6 receptor antagonistic structure-activity relationship are disclosed. The nature and position of substituents, which affect their receptor antagonistic activity, are analyzed. Among all synthesized derivatives, 3-(3-chlorophenylsulfonyl)-5,7-dimethyl-pyrazolo[1,5-a]pyrimidin-2-yl}-methyl-amine 33 (K-i = 190 pM), (3-phenylsulfonyl-7-methyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine 44 (K-i = 240 pM), (3-phenylsulfonyl-5-metoxymethyl-7-methyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine 50 (K-i = 270 pM), and (3-phenylsulfonyl-5-methyl-7-metoxymethyl-pyrazolo[1,5-a]pyrimidin-2-yl)-methyl-amine 52 (K-i = 280 pM) are the most potent antagonists of the 5-HT6 receptors. (C) 2010 Elsevier Ltd. All rights reserved.